Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
8.08
-0.45 (-5.28%)
Oct 30, 2026, 11:27 AM EDT - Market open
Atara Biotherapeutics Revenue
Atara Biotherapeutics had revenue of $630.00K in the quarter ending June 30, 2026, a decrease of -96.42%. This brings the company's total for the last twelve months to $6.19M, down -96.72% year-over-year. In the year 2025, Atara Biotherapeutics had annual revenue of $120.77M, down -6.33%. That makes Atara Biotherapeutics the 39,248th largest company in the world by revenue and 5,192nd in the United States.
Revenue (ttm)
$6.19M
Revenue Growth
-96.72%
P/S Ratio
13.82
Revenue / Employee
$619,400
Employees
10
Market Cap
81.10M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 120.77M | -8.17M | -6.33% |
| Dec 31, 2024 | 128.94M | 120.37M | 1,404.02% |
| Dec 31, 2023 | 8.57M | -55.00M | -86.51% |
| Dec 31, 2022 | 63.57M | 43.23M | 212.55% |
| Dec 31, 2021 | 20.34M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 63.82M |
| Rani Therapeutics Holdings | 4.88M |
| Equillium | 4.39M |
| Rallybio | 434.00K |
| Genelux | 8.00K |
ATRA News
- 16 days ago - Atara partner receives acceptance by FDA of BLA resubmission for tabelecleucel - TheFly
- 16 days ago - Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration - Business Wire
- 4 weeks ago - Atara reports resubmission of tabelecleucel BLA to FDA - TheFly
- 4 weeks ago - Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration - Business Wire
- 2 months ago - Atara Biotherapeutics reports Q2 EPS (32c), consensus (32c) - TheFly
- 2 months ago - Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress - Business Wire
- 2 months ago - Atara Biotherapeutics Quarterly report: Q2 2026 - Filings
- 2 months ago - Atara Biotherapeutics Earnings release: Q2 2026 - Filings